BioWorld

June 18, 2003

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today) Read More

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange

Alcohol Abuse In Pregnancy Can Bring On Fetal Alcohol Syndrome, Mental Retardation In The Young

Biomira, Merck KGaA Report Failed Theratope Phase III Trial

BioMarin Aiming To Raise $125M In Convertible Notes

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

Boston Life Sciences Plans Another Altropane Phase III

Amylin Sends Symlin Amendment To FDA, Seeks $150M In Notes

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...